Aldeyra Therapeutics, Inc. (NasdaqCM:ALDX) is scheduled to report Q3 earnings results on November 5, 2020.
The company is expected to report earnings of -$0.27/share on revenue of zero. The consensus earnings per share (EPS) of -$0.27/share is based on a poll of 6 analysts and represents a growth in eps of 60.5% over the same quarter last year, when the company reported earnings of -$0.69/share.
The revenue forecast of zero based on a poll of 6 analysts implies a year-over-year (YoY) growth in revenue of -. Last year the company reported zero in revenue for the quarter.
| Metric | Expected | Prior Year | YoY Change |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | – |
| EPS | -$0.27 | -$0.69 | 60.5% |
Earnings Call Trends
Historically, management has exceeded analyst expectations 4 out of the last 8 tracked quarters, and missed expectations 4 quarters.
What are your expectations from Aldeyra Therapeutics, Inc. for earnings this quarter? Let us know in the comments!
| Quarter | Expected | Reported | Surprise | Result |
|---|---|---|---|---|
| Q2, 2020 | -$0.35 | -$0.25 | 27.9% | Beat |
| Q1, 2020 | -$0.46 | -$0.34 | 26.8% | Beat |
| Q4, 2019 | -$0.70 | -$0.48 | 31.1% | Beat |
| Q3, 2019 | -$0.56 | -$0.69 | -23.7% | Missed |
| Q2, 2019 | -$0.49 | -$0.49 | -0.6% | Missed |
| Q1, 2019 | -$0.44 | -$0.58 | -32.3% | Missed |
| Q4, 2018 | -$0.43 | -$0.39 | 9.1% | Beat |
| Q3, 2018 | -$0.47 | -$0.52 | -9.5% | Missed |
In the following table, we summarize the company’s stock price movements after earnings releases. The “Price Day Prior” column shows the closing stock price on the day before the earnings report, and the “Price Next Day” column shows the stock price at the end of the trading day after the earnings report. After the last earnings report for the period ending June 30, 2020, the stock price reacted by falling −4.4%.
| Report Date | Price Day Prior | Price Next Day | Change % | Result |
|---|---|---|---|---|
| August 6, 2020 | $7.46 | $7.13 | −4.4% | Decline |
| May 7, 2020 | $2.93 | $2.85 | −2.7% | Decline |
| March 12, 2020 | $2.79 | $2.51 | −10.0% | Decline |
| November 7, 2019 | $6.03 | $5.93 | −1.7% | Decline |
Fundamentals And Technical Analysis
Aldeyra Therapeutics, Inc. is currently trading at $6.68/share, up 5.9% for the day. The company is trading at approximately 76.8% of its 52-week high of $8.70/share. The company’s stock price is down −6.3% since the last earnings report and down −12.6% over the previous week. The company’s 14 Day Relative Price Index (RSI) of 43.21 suggests the company is trading in technically neutral territory. The RSI is considered overbought when above 70 and oversold when below 30.
The current share price implies a price-to-earnings (P/E) multiple of −5.24 and a forward P/E multiple of −6.26.
Aldeyra Therapeutics, Inc.’s current share price also implies a price-to-book (P/B) multiple of 4.89. The following table summarizes some other key fundamental ratios:
| Metric | Value |
|---|---|
| Last Reported Fiscal Period Key | FY2020.Q2 |
| Period End Date | June 30, 2020 |
| Stock Price (Current) | $6.68 |
| P/E Ratio | −5.2x |
| P/E Ratio (Fwd) | −6.3x |
| PEG Ratio | −0.4 |
| Total Debt / Total Capital | 5.8% |
| Levered Free Cash Flow | -$42.48 million |
| EV / EBITDA | −4.5x |
Aldeyra Therapeutics, Inc. is a micro-cap stock with a market capitalization of $258.1 million and a total enterprise value of $216.8 million. The company operates in the Healthcare sector and the Biotechnology industry.
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company’s lead product candidate is reproxalap, an ophthalmic solution, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, a sight-threatening retinal disease. The company’s portfolio also consists of ADX-1612, a small molecule heat shock protein 90 (Hsp90) inhibitor for the treatment of lymphoproliferative diseases; and reactive aldehyde species that are pro-inflammatory (RASP) scavengers, such as ADX-629 for treating autoimmune diseases, as well as ADX-103 for the treatment of retinal diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was founded in 2004 and is headquartered in Lexington, Massachusetts.
